Novartis

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Novartis
clinical trials
Kisqali
breast cancer
Flag link:
FDA approves Pharming drug for ultra-rare immunodeficiency disease
FDA approves Pharming drug for ultra-rare immunodeficiency disease
Endpoints
FDA
Pharming
Novartis
leniolisib
APDS
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Novartis pulls the plug on UK-based cardiovascular study
Novartis pulls the plug on UK-based cardiovascular study
Endpoints
Novartis
clinical trials
Leqvio
UK
Cardiovascular
Flag link:
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Fierce Biotech
Flare Therapeutics
funding
Pfizer
Eli Lilly
Novartis
transcription factors
Flag link:
AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Novartis
SMA
Zolgensma
gene therapy
Flag link:
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Sangamo Therapeutics
Novartis
Biogen
neurology
gene regulation therapies
Flag link:
Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer
Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer
Endpoints
Novartis
Tafinlar
Mekinist
pediatric
brain cancer
FDA
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
BioSpace
Mediar Therapeutics
Novartis
Pfizer
fibrosis
Flag link:
After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra
After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra
Fierce Pharma
Novartis
Xiidra
ophthalmology
Flag link:
Seeking to boost shareholder returns, Novartis readies new $11B buyback round
Seeking to boost shareholder returns, Novartis readies new $11B buyback round
Fierce Pharma
Novartis
share repurchase
Flag link:
Sandoz, betting on biosimilar sales, to build new production plant
Sandoz, betting on biosimilar sales, to build new production plant
BioPharma Dive
Sandoz
Novartis
drug manufacturing
Slovenia
biosimilars
Flag link:
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Fierce Pharma
Novartis
Pharma CEOs
Vas Narasimhan
executive pay
restructuring
Flag link:
Novartis ready to head for deep space with Voyager after a year 'kicking the tires'
Novartis ready to head for deep space with Voyager after a year 'kicking the tires'
Fierce Biotech
Novartis
Voyager Therapeutics
Flag link:
Novartis takes step toward expanding supply of in-demand cancer drug
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Novartis
Pluvicto
prostate cancer
Flag link:

Pages